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Differential kinetic profiles 
and metabolism of primaquine enantiomers 
by human hepatocytes
Pius S. Fasinu1, Bharathi Avula1, Babu L. Tekwani1,2, N. P. Dhammika Nanayakkara1, Yan‑Hong Wang1, 
H. M. T. Bandara Herath1, James D. McChesney5, Gregory A. Reichard6, Sean R. Marcsisin6, 
Mahmoud A. Elsohly1,3,4, Shabana I. Khan1,2, Ikhlas A. Khan1,2 and Larry A. Walker1,2*
Abstract 
Background: The clinical utility of primaquine (PQ), used as a racemic mixture of two enantiomers, is limited due to 
metabolism‑linked hemolytic toxicity in individuals with genetic deficiency in glucose‑6‑phosphate dehydrogenase. 
The current study investigated differential metabolism of PQ enantiomers in light of the suggestions that toxicity and 
efficacy might be largely enantioselective.
Methods: Stable isotope 13C‑labelled primaquine and its two enantiomers (+)‑PQ, (−)‑PQ were separately incubated 
with cryopreserved human hepatocytes. Time‑tracked substrate depletion and metabolite production were moni‑
tored via UHPLC–MS/MS.
Results: The initial half‑life of 217 and 65 min; elimination rate constants (λ) of 0.19 and 0.64 h−1; intrinsic clearance 
(Clint) of 2.55 and 8.49 (µL/min)/million cells, which when up‑scaled yielded Clint of 6.49 and 21.6 (mL/min)/kg body 
mass was obtained respectively for (+)‑ and (−)‑PQ. The extrapolation of in vitro intrinsic clearance to in vivo human 
hepatic blood clearance, performed using the well‑stirred liver model, showed that the rate of hepatic clearance of 
(+)‑PQ was only 45 % that of (−)‑PQ. Two major primary routes of metabolism were observed—oxidative deamina‑
tion of the terminal amine and hydroxylations on the quinoline moiety of PQ. The major deaminated metabolite, 
carboxyprimaquine (CPQ) was preferentially generated from the (−)‑PQ. Other deaminated metabolites including 
PQ terminal alcohol (m/z 261), a cyclized side chain derivative from the aldehyde (m/z 241), cyclized carboxylic acid 
derivative (m/z 257), a quinone‑imine product of hydroxylated CPQ (m/z 289), CPQ glucuronide (m/z 451) and the 
glucuronide of PQ alcohol (m/z 437) were all preferentially generated from the (−)‑PQ. The major quinoline oxidation 
product (m/z 274) was preferentially generated from (+)‑PQ. In addition to the products of the two metabolic path‑
ways, two other major metabolites were observed: a prominent glycosylated conjugate of PQ on the terminal amine 
(m/z 422), peaking by 30 min and preferentially generated by (+)‑PQ; and the carbamoyl glucuronide of PQ (m/z 480) 
exclusively generated from (+)‑PQ.
Conclusion: Metabolism of PQ showed enantioselectivity. These findings may provide important information in 
establishing clinical differences in PQ enantiomers.
Keywords: Enantioselectivity, Hepatocytes, Malaria, Metabolism, Primaquine enantiomers, Primaquine metabolites
© 2016 Fasinu et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Malaria Journal
*Correspondence:  lwalker@olemiss.edu 
1 The National Center for Natural Products Research, School of Pharmacy, 
The University of Mississippi, University, MS 38677, USA
Full list of author information is available at the end of the article
Page 2 of 12Fasinu et al. Malar J  (2016) 15:224 
Background
The sustained utility and continued interest in primaquine 
(PQ), even more than six decades after its introduction 
into clinical medicine, underscores its unique therapeutic 
indications [1]. As a prototype 8-aminoquinoline, PQ is 
the only licensed option to treat the relapsing liver stages 
(hypnozoites) of Plasmodium vivax, in addition to its use 
in the prophylaxis of all forms of human malaria [2–5]. 
PQ is also active against mature, infective Plasmodium 
falciparum gametocytes, and there is thus current high 
interest in its use as a gametocytocidal drug for blocking 
transmission of P. falciparum. In areas of emerging drug 
resistance, primaquine has shown effectiveness against 
and in the prevention of the spread of artemisinin-resist-
ant P. falciparum strains [6]. The major drawback in the 
clinical utility of primaquine however, is its haemolytic 
toxicity in individuals with genetic deficiency in glucose-
6-phosphate dehydrogenase (G6PD) [4, 5].
Many attempts have been made to improve the thera-
peutic index of PQ and other 8-aminoquinolines [2]. 
PQ is a chiral drug currently used as a racemic mixture, 
approximating a 50:50 ratio of (+)-(S)- and (−)-(R)-
enantiomers. It has been suggested that the stereo-con-
figuration of PQ side chain may dramatically impact its 
metabolism, toxicity, and anti-malarial activity. More 
than three decades ago, Schmidt et  al. suggested the 
exploration of the differential anti-malarial efficacy and 
toxicity profiles of the individual PQ enantiomers for 
possible improvement of the therapeutic index of PQ 
[7]. However, the lack of an economical stereospecific 
method to prepare individual enantiomers or an effec-
tive practical procedure to resolve the racemate into 
enantiomers delayed further studies on individual PQ 
enantiomers.
An efficient method for the resolution of racemic PQ 
mixture into individual enantiomers and findings on 
enantioselective activity and toxicity profiles in several 
animal models were recently reported [8, 9]. From these 
studies, it was observed that (+)-(PQ) was more active 
than (−)-PQ in suppressive and prophylactic anti-malar-
ial assays as well as Pneumocystis carinii pneumonia effi-
cacy assay in mice [8]. However, for radical curative assay 
in monkeys, previous studies have shown that both PQ 
enantiomers were equally effective [7, 9]. (+)-PQ caused 
higher acute toxicity than (−)-PQ in beagle dogs and 
mouse models. In monkeys, reversible liver damage was 
observed at higher than therapeutic (−)-PQ doses. In 
three different animal models (beagle dogs, humanized 
mouse model and monkeys) (+)-PQ caused higher meth-
aemoglobinemia than (−)-PQ. The observed disparity of 
activity and toxicity profiles of PQ enantiomers in differ-
ent animal models could be attributed to their differen-
tial pharmacokinetics and metabolism. Based on these 
results, it was suggested that (−)-(R)-PQ enantiomer 
may have a better safety margin than the currently used 
racemate and proposed a “phase I” type human study to 
compare pharmacokinetics and tolerability study of PQ 
enantiomers [7, 9].
It had long been speculated that PQ needed metabolic 
activation due to its lack of in vitro activity and toxicity, 
and the observed delayed onset of action in animal mod-
els. PQ treatment failures were reported in subjects with 
impaired cytochrome P450 2D6 (CYP2D6) function [10]. 
Subsequent studies using a CYP2D knock-out mouse 
model found evidence that CYP2D metabolism was a 
prerequisite for the causal prophylactic activity of PQ 
[11]. Differential metabolism of PQ enantiomers in vitro 
by recombinant human CYP2D6 was previously reported 
[12]. The principal CYP2D6-dependent metabolic path-
way of PQ was found to involve the hydroxylation of the 
quinoline ring yielding 2-, 3-, and 4-hydroxyprimaquine, 
PQ-5,6-orthoquinone and dihydroxyprimaquine as the 
major metabolites. PQ-5,6-orthoquinone appeared to be 
the oxidative degradation product of 5-OH-PQ. Synthetic 
5-OH-PQ spontaneously undergoes rapid oxidation 
sequentially to PQ-5,8-quinone-imine and PQ-5,6-or-
thoquinone [13]. Both quinone-imine and orthoquinone 
can generate reactive oxygen species (ROS) through 
redox cycling, hence are possible candidates as the active 
metabolites of PQ. ROS have shown to be responsible 
for both antiparasitic activity and haemotoxity. The rate 
and extent of the generation of these metabolites differ 
significantly with individual PQ enantiomers [12]. Pri-
maquine-5,6-orthoquinone was twice as abundant from 
CYP2D6-catalyzed metabolism of (+)-PQ metabolism 
compared to (−)-PQ. The rate of metabolism in  vitro 
with recombinant human CYP2D6 was significantly 
higher for (+)-PQ compared to (−)-PQ.
In addition to the CYP-mediated oxidation of the qui-
noline ring, oxidative deamination of the terminal amine 
by monoamine oxidase A (MAO) has been identified as 
the other major metabolic pathway of PQ. Oxidation of 
PQ by MAO results in formation of an aldehyde metab-
olite, which is further oxidized or reduced to the stable 
metabolites namely, carboxyprimaqine (CPQ) and PQ-
alcohol, respectively. CPQ had been identified as the 
major circulating human metabolite of racemic PQ [14, 
15]. Pharmacokinetic studies of racemic PQ in mice, 
monkeys and humans have shown that CPQ rapidly 
appeared in the plasma and was predominantly the (−)-
form [9, 15, 16]. The current study is aimed at character-
izing the kinetics of metabolic profiles of the individual 
PQ enantiomers in human hepatocytes, where both the 
CYP and MAO pathways are present.
The primary aim of this study was therefore to char-
acterize the metabolism of the individual enantiomers 
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of PQ in human hepatocytes, while profiling the enan-
tioselective metabolites generated. This is expected to 
provide projections of enantioselective metabolic profiles 
in human. To facilitate identification of metabolites a 1:1 
mixture 13C-(C6)-labelled and normal 12C-PQ was used 
in this study.
Methods
HPLC-grade acetonitrile and methanol were purchased 
from Fisher Scientific (Fair Lawn, NJ, USA). Water 
for the HPLC mobile phase was purified using a Mili-
pore Synergy Water Purification System (Milipore SAS, 
Molsheim, France). PQ diphosphate and formic acid 
were purchased from Sigma (St Louis, MO, USA).
Synthetic chemicals
13C(6)-labelled PQ was prepared [17] and resolved into 
(+)-(S)- and (−)-(R)- enantiomers as previously reported 
[8]. CPQ [18] and CPQ-lactam [19] were prepared using 
the procedures reported. Synthesis of 2-, 3-, and 4-OHPQ 
and PQ alcohol were reported earlier [12].
Synthesis of primaquine alcohol glucuronide
Primaquine alcohol‑β‑d‑2,3,4‑O‑triacetylglucuronide methyl 
ester
Ag2CO3 (414 mg, 1.5 mM) was added potion wise for 2 h 
to a stirring mixture of acetobromo-α-d-glucuronic acid 
methyl ester (398  mg, 1  mM), and primaquine alcohol 
(390 mg, 1.5 mM) in dry toluene (10 mL) at 75 °C and the 
reaction was left overnight. The reaction mixture filtered 
through Celite, and the filtrate was evaporated to dryness 
The product was purified by column chromatography on 
silica gel with hexane:EtOAc (90:10) to give primaquine 
alcohol-O-β-d-2,3,4-O-triacetylglucuronide methyl ester 
(410 mg).
1H NMR δ (CDCl3): 1.08 (3H, d, J  =  4.0  Hz), 1.49 
(4H, m), 1.82 (3H,s), 1.84 (6H, s), 3.41 (4H, m), 3.53 
(3H, s), 3.66 (3H, s), 4.27 (1H, d, J =  8.0  Hz), 4.95 (1H, 
d, J =  8.0  Hz), 5.05 (1H, dd, J =  6.0, 8.0  Hz), 5.35 (1H, 
dd, J =  6.0. 8.0  Hz), 6.10 (1H,s), 6.13 (1H, s), 6.21 (1H, 
d, J = 4.0 Hz), 7.07 (1H, dd, J = 6.0, 4.0 Hz), 7.70 (1H, d, 
J = 6.0 Hz), 8.29 (1H, d, J = 4.0 Hz); HRESIMS [M + H]+ 
m/z 577.2423 (calculated for (C28H36N2O11  +  H)+ 
577.2397).
Primaquine alcohol‑O‑β‑d‑glucuronide
Primaquine alcohol-O-β-d-2,3,4-O-triacetylglucuronide 
methyl ester (350  mg) was dissolved in a mixture of 
MeOH/H2O (5:1)(10 mL) stirred at 0 °C, added ethyl di-
isopropyl amine (2 mL) and continued stirring overnight 
at room temperature. Solvent was evaporated under vac-
uum and the residue was chromatographed on reverse 
phase silica (C-18) column with H2O:MeOH to give pri-
maquine alcohol-O-β-d-glucuronic acid.
1H NMR δ (CD3OD): 8.67 (1H, brs), 8.44(1H, d, 
J = 6.0 Hz), 7.64 (1H, m), 6.48 (1H, s), 5.14 (1H, s), 4.52 
(1H, d, J = 8.0 Hz), 3.88 (3H, s), 3.84 (1H, m), 3.68 (1H, 
m), 3.40 (1H, m), 3.34 (1H, m), 3.20 (2H,m), 1.80 (4H,m), 
1.30 (3H, d, J  =  6.0  Hz); HRESIMS [M  +  H]+ m/z 
437.1884 (calculated for (C21H28N2O8 + H)+ 437.1924).
Synthesis of carboxyprimaquine‑β‑d‑glucuronide
Benzyl 1‑O‑levulinyl‑d‑glucuronate
N-Methyl mopholine (0.25 mL) was added to a mixture 
of benzyl d-glucuronate (426  mg, 1.5  mM), levulinic 
acid (185  mg, 1.6  mM) and HATU (380  mg, 1  mM) in 
anhydrous acetonitrile (10  mL) and the reaction mix-
ture was stirred 2  h at ambient temperature. Reaction 
was quenched with Ambalite H+ resin, filtered and the 
residue was thoroughly washed with CH2Cl2. Combined 
organic extract was evaporated to dryness and chromto-
graphed on silica column with CH2Cl2:MeOH (96:4) to 
give benzyl 1-O-levulinyl-d-glucuronate (550 mg).
1H NMR δ (CDCl3): 2.06 (3H, s), 2.72-2.48 (4H, m), 
3.80-3.58 (4H, m), 4.02 (1H, d, J = 9.6 Hz), 5.15 (2H, s), 
5.60 (1H,d, J = 7.6 Hz), 7.30 (5H, m).
Carboxyprimaquine‑β‑d‑glucuronide benzyl ester
NaBH4 was added portion wise to a mixture of ben-
zyl 1-O-levulinyl-d-glucuronate (275  mg, 0.72  mM) 
and 6-methoxy-8-aminoquinoline (128  mg, 0.8  mM) 
in glacial acetic acid (5 ml) at 20 °C under stirring while 
monitoring the reaction by TLC. Upon completion, the 
reaction was quenched with ice/water, neutralized with 
10  % NaOH and extracted with CH2Cl2. The organic 
extract was dried on anhydrous Na2SO4, evaporated to 
dryness. The product was purified by chromatography 
on silica gel and elution with CH2Cl2/MeOH (5  %) to 
give carboxyprimaquine-β-d-glucuronide benzyl ester 
(260 mg).
Carboxyprimaquine‑β‑d‑glucuronide
Carboxyprimaquine-β-d-glucuronide benzyl ester 
(210 mg) and 10 % Pd/C in EtOH (10 mL) was hydrogen-
ated with H2 (20 psi) for 2 h. Reaction mixture was filtered 
through Celite purified by silica column chromatography 
with CH2Cl2:MeOH to give carboxyprimaquine-β-d-
glucuronide (140 mg).
1H NMR δ (CD3OD): 8.48 (1H, brs), 8.02 (1H, d, 
J = 8.0 Hz), 7.35 (1H, m), 6.38 (1H, d, J = 7.6 Hz), 5.51 
(1H, m), 3.91 (1H, m), 3.84 (3H,s), 3.68 (1H, m), 3.46 (1H, 
m), 3.39 (1H, m), 3.30 (1H, m), 2.54 (2H, m), 1.90 (2H, m), 
1.25 (3H, d, J = 6.4 Hz): 13C NMR δ (CD3OD): 19.1, 30.2, 
30.8, 54.3, 71.6, 72.1, 75.5, 76.0, 94.0, 97.4, 121.5, 130.1, 
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135.1, 143.8, 144.5, 159.5, 172.4: HRESIMS [M + H]+ m/z 
451.1776 (calculated for (C21H26N2O9 + H)+ 451.1717).
Synthesis of (S)‑primaquine‑N‑carbamoyl‑β‑d‑glucuronide
(S)‑primaquine‑N‑carbamoyl‑2,3,4‑O‑triacetyl‑β‑d‑glucuron
ide methyl ester
A solution of 4-dimethylamino pyridine (112  mg, 
0.92 mM) in anhydrous CH3CN (5 mL) was added drop-
wise to a solution of di-tert-butyl dicarbonate (1.2  g, 
5.5 mM) in anhydrous CH3CN (5 mL) at 0 °C under stir-
ring. After 10 min, a solution of (+)-(S)-primaquine free 
amine (1.2 g, 4.6 mM) in anhydrous CH3CN (5 mL) was 
added dropwise and the reaction mixture was stirred for 
further 30  min at 0  °C. Solvent was evaporated under 
reduced pressure and the resulting dark yellow oily 
residue was dissolved in toluene (5 mL), cooled to 0  °C, 
treated dropwise with a solution of methyl 2,3,4-tri-O-
acetyl-d-glucuronnte (1.8  g, 5.5  mM) in toluene (5  mL) 
followed by triethylamine (1.2  mL) and stirred for 2  h 
at 0  °C and another 2  h at room temperature. Solvent 
was evaporated under reduced pressure and the dark 
brown residue was chromatographed on silica column 
and eluted with ethyl acetate/hexane (40:60) to give (S)-
primaquine-N-carbamoyl -2,3,4-O-triacetyl-β-d-glu-
curonide methyl ester (1.80 g).
1H NMR δ (CDCl3): 1.25 (3H, d, J = 6.8 Hz), 1.60 (4H, 
m), 1.99 (9H, brs), 3.15 (2H, m), 3.58 (1H, m), 3.66 (3H, 
s), 3.85(3H, s), 4.12 (1H, d, J  =  10, Hz), 5.31-5.09 (4H, 
m), 5.67 (1H, d, J = 8.4 Hz), 5.94 (1H, brd, J = 8.4 Hz), 
6.23 (1H, s), 6.30 (1H, s), 7.27 (1H, dd, J = 8.4, 7.6 Hz), 
7.88 (1H, d, J  =  8.4  Hz), 8.49 (1H, d, J  =  4.4  Hz); 
HRESIMS [M  +  H]+ m/z 620.2451 (calculated for 
(C29H37N3O12 + H)+ 620.2455).
(S)‑primaquine‑N‑carbamoyl‑β‑d‑glucuronide
Ethyldiisopropyl amine (6  mL) was added to a solu-
tion of primaquine-N-carbamoyl-2,3,4-O-triacetyl-β-d-
glucuronide methyl ester (700  mg, 1.12  mM) in MeOH 
(30  mL) and H2O (6  mL) at 0  °C while stirring. After 
10  min at 0  °C, cooling bath was removed and stirring 
was continued overnight. Solvent was removed under 
reduced pressure and the residue was dissolved in MeOH 
(2  mL), introduced to a Sephadex column (4 ×  30  cm) 
and eluted with methanol (0.5  mL/min) to give 
(S)-primaquine-N-carbamoyl-β-d-glucuronide (284  mg) 
as a pale yellow powder.
1H NMR δ (D6-DMSO): 1.18 (3H, d, J = 6.4 Hz), 1.60 
(4H, m), 3.33-2.99 (7H, m), 3.66 (3H, s), 3.59 (2H, m), 3.80 
(3H, s), 5.16 (1H, d, J = 8.4 Hz), 6.11 (1H, d, J = 8.4 Hz), 
6.24 (1H, d, J =  2.0  Hz), 6.44 (1H, d, J =  2.0  Hz), 7.40 
(1H, dd, J =  8.0, 8.0  Hz), 8.05 (1H, d, J =  8.4  Hz), 8.51 
(1H, d, J = 3.6 Hz); 13C NMR δ (D6-DMSO): 20.6, 26.6, 
33.8, 47.5, 55.4, 72.3, 72.8, 74.8, 77.1, 92.1, 95.4, 96.6, 
122.6, 130.0, 135.0, 135.3, 145.1, 144.7, 155.6, 159.4, 
173.1; HRESIMS [M + H]+ m/z 480.1954 (calculated for 
(C22H29N3O9 + H)+ 480.1982).
Hepatocytes
Pooled mixed-gender cryopreserved metabolism-quali-
fied (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4, UGT2B7, 
UDP-glucuronosyltransferase) primary human hepato-
cytes (catalog number 454504) sourced from free donors 
(who were free of HIV, HBV, HCV and other liver-related 
diseases) were purchased from Corning Life Sciences 
(Woburn MA, USA) and stored in liquid nitrogen until 
use.
Hepatocytes incubations and viability measurements
The cryopreserved hepatocytes were thawed and the cells 
were suspended in recovery medium (Corning Life Sci-
ences). According to the supplier’s instructions, the sus-
pended cells were centrifuged (300g, 5 min), the recovery 
medium discarded and the cells were re-suspended in the 
plating medium. Viability of the suspended hepatocytes 
was computationally determined based on cell counts 
using a Bio-Rad automated cell counter (Hercules, CA, 
USA). The cell density was adjusted to approximately 
1X106 viable cells/mL in the plating media.
PQ, racemic and enantiomers, prepared as a 1:1 mix-
ture of 12-C and 13-C-labelled compounds, were sepa-
rately incubated at a final concentration of 20 µM in the 
cell-containing plating media using the 48-well plate 
at 37 °C under a humidified atmosphere of 95 % air and 
5  % CO2 in an Eppendorf incubator (Hauppauge, NY, 
USA) attached with a shaker set at 75  rpm. A separate 
control incubation of PQ and the two enantiomers in 
the cell-free hepatocyte media was performed to detect 
any non-enzymatically generated product. Metabolic 
reactions were halted by the addition of two volumes 
of ice-cold methanol containing 0.5  µg/mL 6-d3-meth-
oxyprimaquine as an internal standard at predetermined 
time intervals. This mixture was vortexed and kept at 
−20  °C for at least 4  h before further analysis. Parallel 
incubation of substrate-free hepatocytes was performed. 
At each time point, aliquots were taken for cell viability 
measurement.
In preparation for HPLC–MS analysis, samples were 
centrifuged (10,000g, 10  min) and clear supernatants 
were dried using a Speedvac. The dried samples were 
re-suspended in 150 µL methanol, centrifuged and clear 
supernatants were transferred to HPLC sample vials for 
analysis.
Detection, identification and quantification of metabolites
The analytical method for simultaneous analysis of 
primaquine and its metabolites using the Ultra-High 
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Performance Liquid Chromatography-Mass Spectrom-
etry (UHPLC-QToF-MS), as earlier developed and 
reported was employed in this study [16]. Typically, 
total separation and elution of the analytes was achieved 
within 10 min retention time, using the Acquity UPLC™, 
BEH Shield RP18 column (100  mm  ×  2.1  mm I.D, 
1.7  µm) equipped with an LC-18 guard column (Van-
guard 2.1 × 5 mm, Waters Corp., Milford, MA, USA) on 
an ACQUITY UPLC system (Waters Corporation, Mil-
ford, MA, USA) to which a conditioned auto-sampler (at 
20  °C) was attached. Details of the chromatography set-
up are published [16].
Metabolites in the accurate mass data were found using 
the Metabolynx® software. The data were searched using 
predicted metabolite mass, mass defects, isotope, and 
fragmentation patterns. Each sample was subjected to 
data acquisition in full scan and data-dependent posi-
tive MS/MS, targeted MS/MS (ESI positive ionization 
mode) and high-resolution MS (HRMS) modes using the 
Waters ACQUITY™ XEVO QTOF Mass Spectrometer 
(Waters Corporation, Manchester, UK) connected to the 
UHPLC system via an electrospray ionization (ESI) inter-
face. Metabolites were distinguished from artifacts and 
unrelated products by the presence of twin peaks with a 
mass difference of six, arising from the six labels in the 
1:1 mixture of 12-C and 13-C-labelled PQ. The Identifica-
tion of each metabolite was assisted by its HRMS data, 
which were used to calculate their elemental composi-
tions. The full scan mass data were screened and filtered 
using Waters MetaboLynx XS software. The qualitative 
metabolite identification was performed using this soft-
ware package.
In vitro elimination calculations
Initial half-life (t1/2) and elimination rate constants 
(λ = ln2/t1/2) of PQ in hepatocyte incubates were calcu-
lated by log-linear regression of PQ concentrations pro-
filed against time using data from the sampling points 
of the 20  µM PQ incubates [20]. The intrinsic clear-
ance in vitro (CLint in vitro) was calculated from λ and 
the cell density in the respective incubation (number of 
viable hepatocytes per mL at time zero) and scaled up 
to the intrinsic clearance in  vivo (CLint in  vivo) using 
the human liver mass (25.7  g/kg body mass) and the 
hepatocellularity (number of hepatocytes per gram of 
liver = 99 millions cells/g liver) [21]: CLint in vitro = λ/
cell density. CLint in  vivo  =  CLint in  vitro  ×  liver 
mass  ×  heptocellularity. From CLint in  vivo and the 
hepatic blood flow [Q (20.7  mL/min)/kg body mass], 
the hepatic metabolic blood clearance (CLh,b) was pre-
dicted using the well-stirred model: CLh,b  =  (CLint 
in vivo × Q)/(CLint in vivo + Q) [21].
Since this estimation was for comparisons between 
enantiomers only, no corrections were made for the free 
fractions in vitro or in vivo—i.e. they were assumed to be 
identical [21].
Statistical analysis
Intra- and inter-day variations in the data obtained from 
replicated experiments were assessed for significance. 
Replicate agreements were within 5  % variations. All 
results were statistically analyzed for significance by Stu-
dent’s t test using GraphPad Prism (GraphPad Software, 
San Diego, CA).
Results
PQ was incubated in  vitro with human hepatocytes 
(1 million cells/mL) at a final concentration of 20  µM. 
Substrate concentrations, as initially titrated, showed 
optimal metabolism at 20 µM (Km = 37 µM). Although 
this is higher than expected peak plasma concentra-
tions in humans as we earlier reported (<2  µM) [15], 
it approximates expected liver concentrations of PQ, 
which we observed to be—at therapeutic doses about 
20 times higher than plasma in our studies in mice [22]. 
The viable cell counts in the drug-free incubation at the 
predetermined time-points were similar to those of the 
PQ-containing incubates, suggesting the absence of PQ-
induced direct hepatocellular toxicity (Fig. 1a). Hepato-
cyte viability at the 2  h termination time was 88  % of 
the starting value, an indication that the integrity of the 
hepatocytes was not compromised through the incuba-
tion period.
Intrinsic metabolic clearance from hepatocytes
Substrate depletion and metabolite production were 
monitored via UHPLC-MS/MS. By 2 h, 30, 16 and 42 % 
of PQ, (+)-PQ and (−)-PQ, respectively, were depleted 
(Fig. 1b).
The initial half-life, calculated by log-linear regres-
sion of PQ concentrations profiled against time using 
data from the sampling points of the 20  µM incubates, 
was 217 and 65 min for (+)- and (−)-PQ, with elimina-
tion rate constants (ʎ) of 0.19 and 0.64 h−1 respectively. 
The in vitro intrinsic clearance, calculated from ʎ and the 
cell density in the respective incubations, was 2.55 and 
8.49 (µL/min)/million cells, which when upscaled in vivo 
based on known human hepatocellularity (hepatocytes/g 
liver) and liver mass (g/kg body mass) yielded 6.49 and 
21.6 (mL/min)/kg body mass respectively for (+)- and 
(−) PQ. Extrapolation to in  vivo human hepatic blood 
clearance was performed using the well-stirred liver 
model, which showed that the rate of hepatic clearance of 
(+)-PQ was only 30 % that of (−) PQ (Table 1).
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Differential kinetics and profile of metabolites generated 
from PQ enantiomers
From the metabolite profile, two major routes of 
metabolism were observed as earlier reported: oxida-
tive deamination of the side chain terminal amine; and 
hydroxylations on the quinoline moiety [16]. The metab-
olites generated through both the pathways were further 
metabolized by phase II conjugation pathways (Fig.  2). 
The comparative concentrations of the metabolites gen-
erated at 1 h post-incubation is presented in Fig. 3. 
The major deaminated metabolite, CPQ (Fig.  2—1) 
(75 % of which was generated within 30 min), was pref-
erentially generated from the (−)-PQ, when compared 
to (+) PQ (about 8:1 at early time points) (Fig. 4a). This 
metabolite has been shown earlier to be the major prod-
uct of PQ biotransformation circulating in the plasma 
of mice [23], monkeys [9] and humans [15]. It is formed 
through the oxidative deamination of the 8-N-aminoalkyl 
side chain of PQ to an intermediate PQ aldehyde which 
is further converted to the carboxylic acid by an alde-
hyde dehydrogenase. The PQ aldehyde formed from PQ 
may also undergo a reduction reaction to form the pri-
maquine alcohol (m/z 261; Fig.  2—2), or cyclization of 
the side chain through the loss of a water molecule (m/z 
241, Fig. 2—3). Further metabolism of CPQ involves the 
elimination of water and cyclization to the 8-amino group 
forming a lactam product (m/z 257, Fig. 2—4). CPQ and 
the PQ alcohol undergo conjugation reactions with glu-
curonides (m/z 451 and 437 respectively; Fig. 2—5, 6) is 
also formed from hydroxylated CPQ. These metabolites 
of the oxidative deamination of the amino side chains 
were preferentially generated from the (−)-PQ compared 
to (+)-PQ (Fig. 5a, b, c). 
A major product of the quinoline ring oxidation identi-
fied was the one that corresponds to an m/z 274, formed 
by hydroxylation of PQ (Figs. 2—8) and subsequent dehy-
drogenation to the quinone-imine. This ring oxidation 
product was preferentially formed from (+)-PQ com-
pared to (−)-PQ (2:1) (Fig. 5d). Site of hydroxylation on 
the quinolone ring could not be established unequivo-
cally at present, but based on other studies, hydroxy-
lation of the 5-position is unlikely due to instability of 
this hydroxylation product which is rapidly converted 
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(±)‑primaquine and its (+)‑, and (−)‑enantiomers in primary human 
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Table 1 The intrinsic clearance of  PQ and  its enantiomers 
in human hepatocytes
λ elimination rate constant, Clint intrinsic clearance, CLh,b hepatic blood 
clearance
a λ is taken as the -slope of the linear portion of the log-linear regression 
(0-60 min)
b Half-lives computed from (t1/2 = ln(2)/
c (ln2/T1/2)/mio viable cells× 1000
d (CLint/1000) ∗ (cells/g/liver) ∗ (g liver / kg body weight). Hepatocellularity is 
given as 99 million cells/g liver; average human liver weight is 25.7 g/kg body 
mass
e CLh = (Qh ∗ CLint, scaled)/(Qh+ CLint, scaled) Qh hepatic blood flow (well-
stirred liver model) is given as 20.7 (mL/min)/kg body mass
f Qh (mL/min/kg body weight): 55 (rat); 30.9 (dog); 43.6 (monkey); 20.7 (human)
(±)‑PQ (+)‑PQ (−)‑PQ
Time interval (min) for calculation  
of elimination rate constant
0–60 0–60 0–60
λ (h−1)a 0.34 0.19 0.64
t½ (h)b 2.03 3.62 1.09
t½ (min) 121.8 217 65
CLint in vitro [(mL/h)/million cellsc] 0.273 0.153 0.509
CLint in vitro [(µL/min)/million cells] 4.55 2.55 8.49
CLint in vivo [(L/h)/kg body mass]d 0.69 0.39 1.30
CLint in vivo [(mL/min)/kg body mass] 11.58 6.49 21.60
CLh,b [(L/h)/kg body mass]
e 0.45 0.30 0.63
CLh,b [(mL/min)/kg body mass] 7 5 11
CLh,b (% hepatic blood flow)f 36 24 51
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to PQ-5,6 orthoquinone. Three other metabolites cor-
responding to m/z 274 were also observed, which were 
exclusively generated by (+)-PQ.
In addition to the ring hydroxylations and side-chain 
terminal amine oxidative deamination pathways, two 
other metabolites were identified, which were generated 
through conjugation directly on the PQ side chain termi-
nal amine. A prominent conjugate (m/z 422; Fig.  2—9), 
identified as a glycosylated PQ, was generated. Formation 
of this metabolite showed a biphasic increase, peaking by 
30 min. This metabolite was preferentially generated from 
(+)-PQ rather than (−)-PQ (Fig.  6a). This glycosylated 
conjugate of PQ was also formed non-enzymatically 
in the cell-free media (Fig.  6b). A linearly accumulating 
metabolite (m/z 480; Fig. 2—10) over the 2 h time course 
was identified as an N-carbamoyl glucuronide of PQ, and 
was exclusively generated from (+)-PQ (Fig. 6c).
Other metabolites were detected but with too minute 
peak areas to profile. These include trace amounts of 
2- and 4-hydroxyprimaquine (Fig. 2—11 and 12), which 
Fig. 2 Putative identities and predicted structures of primaquine metabolites generated in human hepatocytes, as determined through MS/MS 
fragmentation, twin peak detection on the UHPLC chromatogram and prediction by Waters’ Metabolynx® software package
Page 8 of 12Fasinu et al. Malar J  (2016) 15:224 
were exclusively generated from the (+)-PQ. Figure  2 
presents the putative structural identities of the metabo-
lites of PQ in human hepatocytes.
Discussion
Pharmacological and toxicological activities of PQ have 
been attributed to the metabolites of the drug, presum-
ably generated through CYP-mediated pathways [24, 25]. 
Until recently, understanding regarding the nature of 
metabolites and pathways involved in formation of these 
metabolites has been incomplete. Application of sta-
ble 13C isotope labeling of PQ, development of sensitive 
UHPLC-MS/MS methods for analysis and availability of 
synthetic metabolites have provided the tools necessary 
for more accurate identification and quantification of PQ 
metabolites [16]. However, the situation has been further 
complicated by the reports regarding differential phar-
macological, toxicological and pharmacokinetics profile 
of enantiomers of PQ [7–9, 15]. Therefore, it is important 
to get a more complete picture of the metabolism and 
pharmacokinetics of PQ especially the differential quali-
tative, quantitative and kinetic profiles of the metabolites 
generated from individual PQ enantiomers. In the cur-
rent study, the enantiomers of PQ have been shown to 
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have differential metabolic and pharmacokinetic profiles 
in human hepatocytes in vitro.
The results presented herein have predicted that the 
initial half-life (as well as other pharmacokinetic param-
eters derived therefrom) of (+)-PQ was more than three 
times longer than that that of (−)-PQ. MAO and CYP 
are known to be involved in the phase I hepatic metabo-
lism of PQ [26]. A majority of the metabolites identified 
in this study appeared to be generated through MAO-
mediated oxidative deamination of PQ. CPQ, the product 
of the sequential oxidative deamination of the 8-N-ami-
noalkyl side chain by MAO and oxidation of the resulting 
PQ-aldehyde was the most abundant primary metabolite 
of PQ and was preferentially generated from the (−)-
PQ (about 8 times higher than in (+)-PQ at the early 
time points). These results support our previous data on 
in vivo pharmacokinetics of PQ enantiomers in rodents, 
primates and humans as well in vitro results with freshly 
isolated human hepatocytes [9, 15]. It is noteworthy that 
all the metabolites formed via the oxidative deamina-
tion of the 8-N-aminoalkyl side chain were consistently 
more abundant from the (−)-PQ than (+)-PQ. A recent 
pharmacokinetic study in human [15] showed that CPQ 
appeared readily in plasma after the administration of 
racemic primaquine and at peak, its concentration was 
15 times higher from (−)-PQ than from (+)-PQ. In fact, 
in some human subjects, the observed CPQ was almost 
exclusively of the minus enantiomer [15]. Thus, reactions 
on the amino side-chain appeared to be the major clear-
ance pathway of (−)-PQ.
Only two ring-hydroxylated PQ metabolites attributa-
ble to CYP pathway were present in substantial amounts. 
They were identified by accurate mass as quinone-imine 
metabolites of hydroxylated PQ and CPQ (m/z 274 and 
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289 respectively). Traces of other hydroxylated metabo-
lites were observed, including the 2-OH and 4-OH-PQ, 
and three other quinone imines (m/z 274). The position 
of the carbonyl group of these metabolites could not be 
determined by mass analysis. Stability of the keto-imines 
however, suggests that the keto group is unlikely to be 
present at C-5 of the quinoline ring, as for this metabo-
lite, a rapid degradation with demethylation of the 
6-methoxy is observed.
In previous studies with recombinant human CYP2D6, 
substantial depletions of PQ enantiomers (50 and 30  % 
for (+)- and (−)-PQ, respectively) were observed dur-
ing a 2  h incubation period, and CYP2D6 preferentially 
converted (+)-PQ to its PQ-5,6-orthoquinone and 
2-hydroxyprimaquine [12]. Meanwhile, in the current 
study, only trace amounts of primary ring oxidative prod-
ucts were detected with hepatocyte incubation, all of 
which were exclusively generated from the (+)-PQ. The 
low quantities of the primary ring hydroxylation prod-
ucts, especially those derived from the 5-OH PQ, which 
has been deemed an important active metabolite [25] 
could possibly be due to rapid degradation or conjuga-
tion with other products. Further studies are required to 
resolve this issue.
The formation of the phase II conjugation reaction 
metabolite, identified as an N-carbamoyl glucuronide 
of PQ accounted for most of the (+)-PQ consumption. 
Identity of N-carbamoyl glucuronide of PQ was con-
firmed by comparison of its HPLC retention time and 
MS/MS fragmentation properties with the synthetic 
standard. It accumulated linearly over time and was the 
major product after prolonged incubation of PQ with 
human hepatocytes. The formation of this carbamoyl glu-
curonide of PQ as a putative metabolite in the incubation 
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mixture of racemic PQ with pooled human hepatocytes 
was previously reported [26]. In the current studies, this 
appears to be the quantitatively predominant metabo-
lite of (+)-PQ in the human hepatocytes, and we have 
also observed it in plasma and urine of human subjects 
receiving primaquine (manuscript in preparation). Such 
N-carbamoyl glucuronides are unusual, but have been 
reported as minor products for other drugs containing 
primary and secondary amines [27, 28]. Incubation of 
these drugs in a high CO2 environment with UDP-glucu-
ronyltransferases can readily yield the carbamoyl glucu-
ronides. It is, however, somewhat surprising that in the 
hepatocytes, this product is enantioselectively formed.
Another unexpected metabolite observed was an 
apparent glucose conjugate of PQ. The biphasic kinet-
ics of formation of PQ-glucose conjugate suggests that 
formation of this metabolite may also depend on other 
metabolic reactions in the hepatocytes. It would be inter-
esting to further investigate the pathway(s) involved in 
formation of this metabolite. The earlier small peak of 
formation of PQ-glucose conjugate may not be enzyme-
dependent, since formation of this conjugate could be 
observed even in cell-free control incubations.
As observed against time of incubation, metabo-
lite profiles showed different shapes, suggesting varia-
tion in kinetics and disposition. The interplay of factors 
including multiple enzyme involvement, dependence of 
one metabolite on the formation of the other, possible 
interactions among the metabolites might be responsi-
ble for the varying kinetics of formation of the different 
metabolites.
Conclusion
The enantiomers of PQ showed significant variation 
in in  vitro pharmacokinetics as well as metabolite gen-
eration in human hepatocytes. The in  vitro clearance 
of (−)-PQ is three times faster than that of (+)-PQ in 
hepatocytes. Trace amounts of ring oxidation products 
were observed with (+)-PQ while (−)-PQ was preferen-
tially metabolized by oxidative deamination of the termi-
nal amine on the N-8 alkyl amino side-chain. Overall, the 
ring oxidation products appeared to be formed in limited 
amounts. A phase II conjugation reaction metabolite 
N-carbamoyl glucuronide of PQ was identified as a major 
metabolite, which was exclusively formed from (+)-PQ. 
Another PQ conjugate formed by apparent N-glucosyla-
tion was preferentially formed with (+)-PQ. These find-
ings enhance the understanding of the pathways of PQ 
metabolism, and further inform the enantioselectivity of 
its metabolic profiles.
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